- Home
- ACIU vs BNY Comparison
ACIU vs BNY Comparison
Compare ACIU & BNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- BNY
- Stock Information
- Founded
- ACIU 2003
- BNY 2001
- Country
- ACIU Switzerland
- BNY United States
- Employees
- ACIU N/A
- BNY N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- BNY Trusts Except Educational Religious and Charitable
- Sector
- ACIU Health Care
- BNY Finance
- Exchange
- ACIU Nasdaq
- BNY Nasdaq
- Market Cap
- ACIU 213.3M
- BNY 247.3M
- IPO Year
- ACIU 2016
- BNY N/A
- Fundamental
- Price
- ACIU $2.90
- BNY $10.31
- Analyst Decision
- ACIU Strong Buy
- BNY
- Analyst Count
- ACIU 2
- BNY 0
- Target Price
- ACIU $10.00
- BNY N/A
- AVG Volume (30 Days)
- ACIU 343.9K
- BNY 52.7K
- Earning Date
- ACIU 11-04-2025
- BNY 01-01-0001
- Dividend Yield
- ACIU N/A
- BNY 3.93%
- EPS Growth
- ACIU N/A
- BNY N/A
- EPS
- ACIU N/A
- BNY N/A
- Revenue
- ACIU $36,362,036.00
- BNY N/A
- Revenue This Year
- ACIU N/A
- BNY N/A
- Revenue Next Year
- ACIU $1,022.98
- BNY N/A
- P/E Ratio
- ACIU N/A
- BNY N/A
- Revenue Growth
- ACIU 86.71
- BNY N/A
- 52 Week Low
- ACIU $1.43
- BNY $8.60
- 52 Week High
- ACIU $3.99
- BNY $10.80
- Technical
- Relative Strength Index (RSI)
- ACIU 47.76
- BNY 71.36
- Support Level
- ACIU $2.89
- BNY $10.16
- Resistance Level
- ACIU $3.21
- BNY $10.23
- Average True Range (ATR)
- ACIU 0.33
- BNY 0.11
- MACD
- ACIU -0.08
- BNY -0.00
- Stochastic Oscillator
- ACIU 3.95
- BNY 71.09
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About BNY BlackRock New York Municipal Income Trust
Blackrock NY Municipal Income Tr investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes and New York State and New York City personal income taxes as is consistent with its investment policies and prudent investment management.